This growing Houston company is providing industrial industries with smart analytics. Getty Images

A Houston-based analytics-focused company is gearing up for growth in 2019 and plans to staff up its headquarters and remote offices abroad.

Arundo Analytics Inc. brings industrial companies — which sometimes are slow to adopt brand-new technology — into the world of machine learning and advanced analytics to help boost revenue, cut costs and reduce risks.

The startup's enterprise software gives asset-heavy industrial businesses "a virtual window into their day-to-day operations," says Stuart Morstead, co-founder and chief operating officer of Arundo. Among the operations that benefit from software are equipment maintenance, safety, logistics and scheduling.

Morstead points out that most industrial companies that encounter issues with operations such as equipment maintenance "lack the data science and software capabilities to drive value from insights into their daily operations."

Arundo aims to solve that problem by incorporating machine learning and advanced analytics — the kind of innovations emanating from the likes of Amazon, Google, and IBM — into everyday business operations at industrial companies, says Morstead, a former partner at consulting firm McKinsey & Co. and a graduate of Rice University.

Aside from its broad enterprise software, Arundo supplies out-of-the-box applications that tackle individual industrial challenges like flow metering for the offshore oil and gas industry and monitoring the condition of equipment. The virtual cloud-based multiphase flow meter is sold as part of a software package from industrial technology giant ABB.

More than 50 of Arundo's estimated 110 employees work on that technology from the startup's headquarters in downtown Houston. To propel its growth, Arundo plans to add employees this year in Houston as well as its other offices in Canada, Norway, Sweden and the United Kingdom, according to Morstead.

In 2016, Arundo graduated from Stanford University's StartX accelerator program. A year later, Arundo was named to the MIT STEX25 accelerator program by the Massachusetts Institute of Technology Startup Exchange.

Since its founding in 2015, Arundo has raised more $35 million in capital, including a Series A round of $28 million that closed in the first half of 2018. Investors include Sundt AS, Stokke Industri, Horizon, Canica, Strømstangen, Arctic Fund Management, Stanford-StartX Fund and Northgate Partners.

Aside from drawing more funding in 2018, the startup set up several strategic partnerships designed to increase the adoption of Arundo's software in sectors such as oil and gas, manufacturing, shipping, construction and maritime. Among the new partners are Dell Technologies, DNV GL's Veracity platform and WorleyParsons.

Going forward, Morstead says Arundo aims to bring its software expertise, business prowess and "world-class data science" to even more industrial companies and their physical assets as part of the global Industrial Internet of Things sector. That market is projected to approach $1 trillion by 2025, up from $100 billion in 2016.

To be sure, Arundo is competing in a market that's rife with opportunity. Consulting firm Accenture estimates the IIoT market could add $14.2 trillion to the global economy by 2030.

"Arguably the biggest driver of productivity and growth in the next decade, the Industrial Internet of Things will accelerate the reinvention of sectors that account for almost two-thirds of world output," the Accenture report says.

Tor Jakob Ramsøy, founder and CEO of Arundo, certainly grasps the enormous potential of IIoT.

"Asset-heavy companies can no longer afford to make business decisions based on an incomplete view of their organization," Ramsøy, a former McKinsey partner, said in a 2018 news release. "By combining deep data and [artificial intelligence] knowledge with decades of cumulative experience in enterprise consulting, Arundo is ushering in a new era in IIoT."

Tracking performance

Courtesy of Arundo

Arundo's Condition & Performance Monitoring Software can easily be plugged into a company's system and track its equipment using cloud technology.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston space company lands latest NASA deal to advance lunar logistics

To The Moon

Houston-based space exploration, infrastructure, and services company Intuitive Machines has secured about $2.5 million from NASA to study challenges related to carrying cargo on the company’s lunar lander and hauling cargo on the moon. The lander will be used for NASA’s Artemis missions to the moon and eventually to Mars.

“Intuitive Machines has been methodically working on executing lunar delivery, data transmission, and infrastructure service missions, making us uniquely positioned to provide strategies and concepts that may shape lunar logistics and mobility solutions for the Artemis generation,” Intuitive Machines CEO Steve Altemus says in a news release.

“We look forward to bringing our proven expertise together to deliver innovative solutions that establish capabilities on the [moon] and place deeper exploration within reach.”

Intuitive Machines will soon launch its lunar lander on a SpaceX Falcon 9 rocket to deliver NASA technology and science projects, along with commercial payloads, to the moon’s Mons Mouton plateau. Lift-off will happen at NASA’s Kennedy Space Center in Florida within a launch window that starts in late February. It’ll be the lander’s second trip to the moon.

In September, Intuitive Machines landed a deal with NASA that could be worth more than $4.8 billion.

Under the contract, Intuitive Machines will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. The initial round of NASA funding runs through September 2029.

Play it back: Houston home tech startup begins 2025 with fresh funding

HOUSTON INNOVATORS PODCAST EPISODE 272

One of the dozen or so Houston startups kicking of the new year with fresh funding is SmartAC.com, a company that's designed a platform that enables contractors in the HVAC and plumbing industries to monitor, manage, and optimize their maintenance memberships through advanced sensors, AI-driven diagnostics, and proactive alerts.

Last month, the SmartAC.com raised a follow-on round with support from local investor Mercury to continue growth and expansion of the product, which has evolved on many ways since the company launched in 2020, emerging from stealth with $10 million raised in a series A. In a May 2023 interview for the Houston Innovators Podcast, Founder and CEO Josh Teekell explained how he embraced the power of a pivot.

The company's sensors can monitor all aspects of air conditioning units and report back any issues, meaning homeowners have quicker and less costly repairs. While SmartAC.com started with providing the service and tech to homeowners directly, Teekell says he's had a greater interest in working with plumbers and HVAC companies who then deploy the technology to their customers.

"It became quite evident that homeowners don't care about air conditioning really at all until their system breaks," Teekell says on the show. "The technology is really built around giving those contractors as another way to gain a customer relationship and keep it."

Revisit the podcast episode below where Teekell talks about SmartAC.com's last raise.

SmartAC.com's previous round in 2023 — a $22 million series B — was used grow its team that goes out to deploy the technology and train the contractors on the platform.

"We've been very fortunate to get some of the biggest names in Houston on our cap table," Teekell says in the May 2023 conversation. "Since we're raising a bunch of money locally, everyone understands what a pain air conditioning can be."

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.